Dr. Vachhani discusses several exciting agents in clinical trials that might help us further improve outcomes for myelofibrosis patients in the future.

Dr. Vachhani addresses the wide spectrum of symptom burden and other disease manifestations in the presentation of myelofibrosis, and the need to appropriately risk stratify each patient.

Dr. Vachhani discusses challenges in the diagnosis of myelofibrosis, as well as the evolving risk stratification scoring systems that have emerged over the last several years.

Dr. Haris Ali and Dr. Andrew Kuykendall share their perspectives on combination therapies that will have an impact on future clinical practice in MF.

In this activity, Dr. Oh discusses updates on JAK inhibitors, a pivotal drug class in the treatment of myelofibrosis.

Despite therapeutic advances in myeloproliferative neoplasms (MPNs), it is often challenging to determine the optimal treatment course for patients in this setting. In this article, Prithviraj Bose, MD, and Ruben A. Mesa, MD, explore two challenging case scenarios and discuss the data supporting best practice for treating these patients. For other case discussions in MPN, please click here to access the CME-accredited activity, “Myeloproliferative Neoplasms: Integrating New Therapies into Challenging Case Scenarios.” Also, please note that the article contains hyperlinks to currently enrolling clinical trials for your convenience.

This activity summarizes key data from studies investigating novel agents and treatment strategies that are needed to expand therapeutic options for patients who have myelofibrosis.

For more information on the evolving treatment landscape in myelofibrosis, please view the CE Education activity here.

In this activity, two experts discuss recent data on JAK2 inhibitors such as the approval of fedratinib and promising emerging data from trials evaluating pacritinib and momelotinib.

For more information on the evolving treatment landscape in myelofibrosis, please view the CE Education activity here.

Case studies presented by Dr. Bose highlight emerging treatment options for patients with myelofibrosis after JAK inhibitor "failure."

For more information on managing your patients with myelofibrosis, please view the CE Education activity here

This newsletter discusses approaches to inhibit JAK2, as well as other combination approaches with ruxolitinib to maximize efficacy for patients with myelofibrosis.

For more information on managing your patients with myelofibrosis, please view the CE Education activity here